MIRDcalc & OLINDA/EXM Dosimetry Software Analysis by SPECT/CT Scan Data of Lu-177 DOTATATE Radionuclide Therapy of NET Patients

Year : 2025 | Volume : 15 | Issue : 02 | Page : –
    By

    Madhulika Mehrotra Mehrotra,

  • Prashant Mishra,

  • Saurabh Sharma,

  • Preethi Deenadayalan,

  1. Women Scientist Fellow, Department of Nuclear Medicine, AIIMS, Ansari Nagar East, New Delhi, India.
  2. Student, Department of Nuclear Medicine, AIIMS, Ansari Nagar East., New Delhi, India
  3. Student, Department of Nuclear Medicine, AIIMS, Ansari Nagar East, New Delhi, India
  4. Clinical Application Specialist, Mediso, Nuclear Medsystems India Pvt Ltd, Delhi, India., Mediso, Nuclear Medsystems India Pvt Ltd, Delhi, India.

Abstract

document.addEventListener(‘DOMContentLoaded’,function(){frmFrontForm.scrollToID(‘frm_container_abs_190842’);});Edit Abstract & Keyword

Accurate dosimetry is essential in nuclear medicine for optimizing radionuclide therapies and ensuring patient safety. In Radiopharmaceutical dosimetry the Medical Internal Radiation Dosimetry (MIRD)Society is the pioneer in organ-level dosimetry providing the fundamental basis for commonly used clinical and research dosimetry software like MIRDOSE and OLINDA/EXM. Recently, in MIRD Pamphlet No. 28, Part 1, the MIRD committee of the Society of Nuclear Medicine and Medical Imaging presented a new Software Tool; MIRDcalc, for organ-level and sub-organ tissue dosimetry, based on a standard Excel spreadsheet platform to enhance personalized internal dosimetry. This study evaluates and compares the internal dosimetry software MIRDcalc and OLINDA/EXM for calculating absorbed and effective doses in neuroendocrine tumor (NET) patients treated with Lutetium-177 DOTATATE, based on quantitative SPECT/CT imaging data. MIRDcalc, a freely accessible Excel-based dosimetry tool, integrates updated anatomical models, user-friendly interfaces, and quality control utilities. Its performance was assessed against OLINDA/EXM, a widely used commercial software, and benchmarked using the standardized absorbed radiation dose calculation equations, described in MIRD primer 2022. Dose estimates for key organs were derived using both platforms, and results demonstrated a high level of concordance between the two methodologies. Minor discrepancies in absorbed dose values were attributed to differences in underlying phantom models, organ definitions, and dose calculation algorithms. The analysis underscores MIRDcalc’s viability as a research-grade tool for personalized dosimetry, offering comparable accuracy to established systems like OLINDA/EXM. Future work should focus on expanding personalized dosimetry, especially for Lu177 DOTATATE, NET patients for Radionuclide therapy capabilities and validating models across broader clinical datasets.

Keywords: MIRDcalc, OLINDA/EXM, Lu-177 DOTATATE, absorbed dose, effective dose, internal dosimetry, SPECT/CT, radionuclide therapy

[This article belongs to Journal of Nuclear Engineering & Technology ]

How to cite this article:
Madhulika Mehrotra Mehrotra, Prashant Mishra, Saurabh Sharma, Preethi Deenadayalan. MIRDcalc & OLINDA/EXM Dosimetry Software Analysis by SPECT/CT Scan Data of Lu-177 DOTATATE Radionuclide Therapy of NET Patients. Journal of Nuclear Engineering & Technology. 2025; 15(02):-.
How to cite this URL:
Madhulika Mehrotra Mehrotra, Prashant Mishra, Saurabh Sharma, Preethi Deenadayalan. MIRDcalc & OLINDA/EXM Dosimetry Software Analysis by SPECT/CT Scan Data of Lu-177 DOTATATE Radionuclide Therapy of NET Patients. Journal of Nuclear Engineering & Technology. 2025; 15(02):-. Available from: https://journals.stmjournals.com/jonet/article=2025/view=0


document.addEventListener(‘DOMContentLoaded’,function(){frmFrontForm.scrollToID(‘frm_container_ref_190842’);});Edit

References

1. Stelson AT, et al. A history of medical internal dosimetry. Health Phys. 1995;69:766–782.
2. Loevinger R, et al. A schema for absorbed-dose calculations for biologically-distributed radionuclides, MIRD Pamphlet No. 1, J Nucl Med. 9 Suppl. 1968;1:7–14.
3. Loevinger R, et al. MIRD Primer for Absorbed Dose Calculations, The Society of Nuclear Medicine. New York: MIRD; 1991.
4. Bolch WE, et al. A generalized schema for radiopharmaceutical dosimetry — standardization of nomenclature, MIRD Pamphlet No. 21. J Nucl Med. 2009;50:477–484.
5. Stabin MG. MIRDOSE: Personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 1996;37:538–546.
6. Stabin MG, Siegel JA. Physical models and dose factors for use in internal dose assessment. Health Phys. 2003;85:294–310.
7. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: The second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023–1027.
8. Kesner AL, Carter LM, Ramos JC, Lafontaine D, Olguin EA, Brown JL, et al. MIRD pamphlet no.28, part 1: MIRDcalc—A software tool for medical internal radiation dosimetry. J Nucl Med. 2023 Jul 1;64(7):1117–24.
9. Carter LM, Ramos JC, Olguin EA, Brown JL, Lafontaine D, Jokisch DW, et al. MIRD pamphlet no. 28, part 2: Comparative evaluation of MIRDcalc dosimetry software across a compendium of diagnostic radiopharmaceuticals. J Nucl Med. 2023 Aug 1;64(8):1295–303.
10. ICRP publication 103: The 2007 recommendations of the International Commission on Radiological Protection. Ann ICRP. 2007;37:1–332.
11. Mattsson S, Johansson L, Svegborn LS, et al. ICRP publication 128: radiation dose to patients from radiopharmaceuticals: a compendium of current information related to frequently used substances. Ann ICRP. 2015;44:1–321.
12. Grosswendt, Bernd. “ICRP publication 110.” (2012):124–126.
13. Bolch WE, Eckerman K, Endo A, Hunt JG, Jokisch DW, Kim CH, et al. ICRP publication 143: Paediatric reference computational phantoms. Annals of the ICRP. 2020 Feb;49(1):5–297.
14. Bolch WE, Jokisch D, Zankl M, Eckerman KF, Fell T, Manger R, et al. ‘ICRP Publication 133: The ICRP computational framework for internal dose assessment for reference adults: Specific absorbed fractions’. Ann ICRP, 2016;45:5–73.
15. Gear JI, Cox MG, Gustafsson J, Gleisner KS, Murray I, Glatting G, et al. ‘EANM practical guidanceon uncertainty analysis for molecular radiotherapy absorbed dose calculations’. Eur J Nucl Med Mol Imaging. 2018;45:2456–74.
16. Loevinger R, Budinger TF, Watson EE. MIRD Primer for Absorbed Dose Calculations. Soc Nucl Med Mol Imaging. 1991.
17. Bartlett RM, Bolch WE, Brill AB, et al. MIRD Primer 2022: A Complete Guide to Radiopharmaceutical Dosimetry. Soc Nucl Med Mol Imaging. 2022.
18. Dewaraja YK, Frey EC, Sgouros G, Brill AB, Roberson P, Zanzonico PB, et al. MIRD pamphletno. 23: Quantitative SPECT for patient-specific 3-dimensional dosimetry in internal radionuclide therapy. J Nucl Med. 2012 Aug 1;53(8):1310–25.
19. Ljungberg M, Celler A, Konijnenberg MW, Eckerman KF, Dewaraja YK, Sjögreen-Gleisner K. MIRD pamphlet no. 26: Joint EANM/MIRD guidelines for quantitative 177Lu SPECT applied for dosimetry of radiopharmaceutical therapy. J Nucl Med. 2016 Jan 1;57(1):151–62.
20. Sgouros G, Bolch WE, Chiti A, Dewaraja YK, Emfietzoglou D, Hobbs RF, et al. ICRU REPORT 96, dosimetry-guided radiopharmaceutical therapy. J ICRU. 2021 Dec;21(1):1–212.
21. IAEA Nuclear Medicine Physics-A Handbook For Teachers And Students, Chapter 18 – Internal Dosimetry; Author: Cecilia Hindorf. IAEA, Vienna: International Atomic Energy Agency, Nuclear Medicine Physics; 2015. https://www.iaea.org/publications/10368/nuclear-medicine-physics.
22. Snyder WS, Ford MR, Warner GG, Watson SB. MIRD Pamphlet No. 11: “S,” Absorbed Dose per Unit Cumulated Activity for Selected Radionuclides and Organs. Soc Nucl Med Mol Imaging. 1975.

23. Olguin E, President B, Ghaly M, Frey E, Sgouros G, Bolch WE. Specific absorbed fractions and radionuclide S-values for tumors of varying size and composition. Phys Med Biol. 2020;65:235015.
24. Capala J, Graves SA, Scott A, et al. Dosimetry for radiopharmaceutical therapy: current practices and commercial resources. J Nucl Med. 2021;62(suppl 3):3S–11S.
25. Katugampola S, Wang J, Rosen A, Howell RW. MIRD pamphlet no. 27: MIRDcell V3, a revised software tool for multicellular dosimetry and bioeffect modeling. J Nucl Med. 2022;63:1441–1449.
26. Roedler HD. Accuracy of internal dose calculations with special consideration of radiopharmaceutical biokinetics. Abstract presented at: Third International Radio- pharmaceutical Dosimetry Symposium. Oak Ridge, TN; October 6, 1980.
27. Andersson M, Johansson L, Minarik D, Leide-Svegborn S, Mattsson S. Effective dose to adult patients from 338 radiopharmaceuticals estimated using ICRP biokinetic data, ICRP/ICRU computational reference phantoms and ICRP 2007 tissue weighting factors. EJNMMI Phys.
2014;1:9.
28. Stabin M, Farmer A. OLINDA/EXM 2.0: the new generation dosimetry modeling code. Nucl Med. 2012;53(suppl 1):585.
29. Stabin MG, Siegel JA. RADAR dose estimate report: a compendium of radiopharmaceutical dose estimates based on OLINDA/EXM version 2.0. J Nucl Med. 2018 Jan 1;59(1):154–60.
30. Subramanian S, He B, Frey E, Jokisch D, Bolch W, Poethko T, et al. Improved Accuracy of S-Value Based Dosimetry: Transitioning from Cristy-Eckerman to ICRP Adult Phantoms.

Regular Issue Subscription Original Research
Volume 15
Issue 02
Received 15/05/2025
Accepted 19/05/2025
Published 19/05/2025
Publication Time 4 Days
113

[first_name] [last_name]

My IP

PlumX Metrics